Genetics of graft-versus-host disease: The major histocompatibility complex

Blood Reviews

Volumn 27, Issue 1, 2013, Pages 1-12

  Petersdorf, Effie W ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cord blood transplantation; Graft versus host disease (GVHD); Haplotype; Hematopoietic cell transplantation (HCT); HLA; Linkage disequilibrium (LD); Major histocompatibility complex (MHC); Single nucleotide polymorphism (SNP); Unrelated donor

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DPB1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR15 ANTIGEN; HLA DRB1 ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BASE MISPAIRING; BASE PAIRING; CHROMOSOME 6; CHROMOSOME SEGREGATION; CORD BLOOD STEM CELL TRANSPLANTATION; GENE LOCUS; GENE MAPPING; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; INNATE IMMUNITY; MICROSATELLITE MARKER; NATURAL KILLER T CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; UNRELATED DONORS;

CYTOKINES; GENE EXPRESSION; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTORS, KIR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872145926     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.10.001     Document Type: Article

References (218)

1. Dausset J. Leuco-agglutinins IV: leuco-agglutinins and bloodtransfusion. Vox Sang 1954, 4:190-198.
2. van Rood J.J., van Leeuwen A. Leukocyte grouping. A method and its application. J Clin Invest 1963, 42:1382-1390.
3. Payne R., Tripp M., Weigle J., Bodmer W., Bodmer J. A new leukocyte isoantigen system in man. Cold Spring Harbor Symp Quant Biol 1964, 29:285-294.
4. Amos D.B. Human histocompatibility locus HL-A. Science 1968, 159:659-660.
5. Bodmer W.F. HLA: what's in a name? A commentary on HLA nomenclature development over the years (Review). Tissue Antigens 1997, 49:293-296.
6. Marsh S.G.E., Albert E.D., Bodmer W.F., et al. An update to HLA nomenclature, 2010. Bone Marrow Transplant 2010, 45:846-848.
7. Shiina T., Hosomichi K., Inoko H., Kulski J.K. The HLA genomic loci map: expression, interaction, diversity and disease (Review). J Hum Genet 2009, 54:15-39.
8. Storb R., Prentice R.L., Hansen J.A., Thomas E.D. Association between HLA-B antigens and acute graft-versus-host disease. Lancet 1983, 2:816-819.
9. Bross D.S., Tutschka P.J., Farmer E.R., et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984, 63:1265-1270.
10. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991, 51:1197-1203.
11. Smyth L.A., Witt C.S., Christiansen F.T., et al. The MHC influences acute graft versus host disease in MHC matched adults undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1993, 12:351-355.
12. Martin P.J., Gooley T., Anasetti C., Petersdorf E.W., Hansen J.A. HLAs and risk of acute graft-vs.-host disease after marrow transplantation from an HLA-identical sibling. Biol Blood Marrow Transplant 1998, 4:128-133.
13. Chapuis B., Von Fliedner V.E., Jeannet M., et al. Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol 1986, 63:51-57.
14. Nimer S.D., Ireland P., Meshkinpour A., Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994, 84:923-927.
15. Nakao S., Takamatsu H., Chuhjo T., et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994, 84:4257-4261.
16. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
17. Shao W., Tian D., Liu C., Sun X., Zhang X. Aplastic anemia is associated with HLA-DRB1*1501 in northern Han Chinese. Int J Hematol 2000, 71:350-352.
18. Maciejewski J.P., Follmann D., Nakamura R., et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001, 98:3513-3519.
19. Oguz F.S., Yalman N., Diler A.S., et al. HLA-DRB1*15 and pediatric aplastic anemia. Haematologica 2002, 87:772-774.
20. Song E.Y., Park S., Lee D.S., Cho H.I., Park M.H. Association of human leukocyte antigen-DRB1 alleles with disease susceptibility and severity of aplastic anemia in Korean patients. Hum Immunol 2008, 69:354-359.
21. Newell L.F., Gooley T., Hansen J.A., et al. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant 2010, 16:1700-1706.
22. Rugman F.P., Ashby D., Davies J.M. Does HLA-DR predict response to specific immunosuppressive therapy in aplastic anaemia?. Br J Haematol 1990, 74:545-546.
23. Nakao S., Yamaguchi M., Saito M., et al. HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure. Am J Hematol 1992, 40:239-240.
24. Ilhan O., Beksac M., Koc H., et al. HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy. Blood 1995, 86:2055.
25. Usman M., Adil S.N., Moatter T., et al. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. JPMA J Pak Med Assoc 2004, 54:251-254.
26. Battiwalla M., Hahn T., Radovic M., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 2006, 107:1970-1973.
27. Stern M., Passweg J., Tiercy J.M., et al. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1169-1175.
28. Davidson J.A., Tate D.G., Poulton K.V., et al. HLA-DR15, reduced relapse rate and improved survival after HLA identical sibling hemopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:493-494.
29. Battiwalla M., Ellis K., Li P., et al. HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012, 18:1302-1308.
30. Parham P. MHC class I molecules and KIRs in human history, health and survival (Review). Nat Rev Immunol 2005, 5:201-214.
31. Tamouza R., Rocha V., Busson M., et al. Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation 2005, 80:140-144.
32. Tamouza R., Busson M., Rocha V., et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006, 82:1436-1440.
33. Hosseini E., Schwarer A.P., Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012, 11:15-21.
34. Danzer M., Polin H., Proll J., et al. Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009, 88:528-532.
35. Ludajic K., Rosenmayr A., Fae I., et al. Association of HLA-E polymorphism with the outcome of hematopoietic stem-cell transplantation with unrelated donors. Transplantation 2009, 88:1227-1228.
36. Furst D., Bindja J., Arnold R., et al. HLA-E polymorphisms in hematopoietic stem cell transplantation. Tissue Antigens 2012, 79:287-290.
37. Boukouaci W., Busson M., Peffault de Latour R., et al. MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood 2009, 114:5216-5224.
38. La Nasa G., Littera R., Locatelli F., et al. The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol 2007, 139:284-288.
39. Chiusolo P., Bellesi S., Piccirillo N., et al. The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone Marrow Transplant 2012, 47:120-124.
40. Boukouaci W., Busson M., Fortier C., et al. Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation. Front Immunol 2011, 2:74.
41. O'Brien M., McCarthy T., Jenkins D., et al. Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. Cell Mol Life Sci 2001, 58:1943-1949.
42. Hviid T.V., Hylenius S., Rorbye C., Nielsen L.G. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003, 55:63-79.
43. Rousseau P., Le Discorde M., Mouillot G., et al. The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003, 64:1005-1010.
44. Keever C.A., Leong N., Cunningham I., et al. HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994, 14:137-145.
45. Keever-Taylor C.A., Bredeson C., Loberiza F.R., et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001, 7:620-630.
46. Nagler A., Brautbar C., Slavin S., Bishara A. Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. Bone Marrow Transplant 1996, 18:891-897.
47. Petersdorf E.W., Longton G.M., Anasetti C., et al. Definition of HLA-DQ as a transplantation antigen. PNAS 1996, 93:15358-15363.
48. Gajewski J., Gjertson D., Cecka M., et al. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 1997, 3:76-82.
49. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998, 339:1177-1185.
50. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998, 92:3515-3520.
51. Petersdorf E.W., Hansen J.A., Martin P.J., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001, 345:1794-1800.
52. Petersdorf E.W., Kollman C., Hurley C.K., et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program experience. Blood 2001, 98:2922-2929.
53. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002, 99:4200-4206.
54. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004, 104:1923-1930.
55. Petersdorf E.W., Anasetti C., Martin P.J., et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004, 104:2976-2980.
56. Ho V.T., Kim H.T., Liney D., et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 37:845-850.
57. Chalandon Y., Tiercy J.M., Schanz U., et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplant 2006, 37:909-916.
58. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
59. Loiseau P., Busson M., Balere M.-L., et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRBI or -DQBI is strongly associated with overall survival. Biol Blood Marrow Transplant 2007, 13:965-974.
60. Bray R.A., Hurley C.K., Kamani N.R., et al. National Marrow Donor Program HLA matching guidelines for unrelated adult hematopoietic cell transplants. Biol Blood Marrow Transplant 2008, 14:45-53.
61. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:885-892.
62. Pawelec G., Ehninger G., Schmidt H., Wernet P. HLA-DP matching and graft-versus-host disease in allogeneic bone marrow transplantation [erratum appears in Transplantation 1987 Apr;43(4):608]. Transplantation 1986, 42:558-560.
63. al Daccak R., Loiseau P., Rabian C., et al. HLA-DR, DQ, and/or DP genotypic mismatches between recipient-donor pairs in unrelated bone marrow transplantation and transplant clinical outcome. Transplantation 1990, 50:960-964.
64. Kato Y., Mitsuishi Y., Cecka M., et al. HLA-DP incompatibilities and severe graft-versus-host disease in unrelated bone marrow transplants. Transplantation 1991, 52:374-376.
65. Varney M.D., Lester S., McCluskey J., Gao X., Tait B.D. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol 1999, 60:532-538.
66. Petersdorf E.W., Gooley T., Malkki M., et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001, 112:988-994.
67. Loiseau P., Espérou H., Busson M., et al. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation [abstract]. Blood 2001, 98. [(Part 1):660a, #2766].
68. Fleischhauer K., Locatelli F., Zecca M., et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006, 107:2984-2992.
69. Shaw B.E., Maldonado H., Madrigal J.A., et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. Tissue Antigens 2004, 63:401-411.
70. Shaw B.E., Gooley T.A., Malkki M., et al. The importance of HLA-DPB1 in unrelated donor haematopoietic cell transplantation. Blood 2007, 110:4560-4566.
71. Crocchiolo R., Zino E., Vago L., et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009, 114:1437-1444.
72. Fleischhauer K., Shaw B.E., Gooley T., et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.[Erratum appears in Lancet Oncol. 2012 Apr;13(4):e134-5]. Lancet Oncol 2012, 13:366-374.
73. Petersdorf E.W., Gooley T., Malkki M., Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 2007, 69(Suppl. 1):25-30.
74. Morishima Y., Yabe T., Matsuo K., et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007, 13:315-328.
75. Ferrara G.B., Bacigalupo A., Lamparelli T., et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001, 98:3150-3155.
76. Kawase T., Morishima Y., Matsuo K., et al. High-risk HLA allele mismatch combinations responsible for severe acute-graft-versus-host disease and implication for its molecular mechanism. Blood 2007, 110:2235-2241.
77. Kawase T., Matsuo K., Kashiwase K., et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009, 113:2851-2858.
78. DeLuca D.S., Khattab B., Blasczyk R. A modular concept of HLA for comprehensive peptide binding prediction. Immunogenetics 2007, 59:25-35.
79. Baxter-Lowe L.A., Maiers M., Spellman S.R., et al. HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States. Biol Blood Marrow Transplant 2009, 15:971-981.
80. Yanover C., Petersdorf E.W., Malkki M., et al. HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in peptide binding specificity on transplant outcome. Immunome Res 2011, 7:4.
81. Spellman S., Klein J., Haagenson M., et al. Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:739-746.
82. Kamani N., Spellman S., Hurley C.K., et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants (Review). Biol Blood Marrow Transplant 2008, 14:1-6.
83. Gluckman E. Milestones in umbilical cord blood transplantation (Review). Blood Rev 2011, 25:255-259.
84. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339:1565-1577.
85. Gluckman E., Rocha V., Arcese W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004, 32:397-407.
86. Kogler G., Enczmann J., Rocha V., Gluckman E., Wernet P. High-resolution HLA typing by sequencing for HLA-A, -B, -C, -DR, -DQ in 122 unrelated cord blood/patient pair transplants hardly improves long-term clinical outcome. Bone Marrow Transplant 2005, 36:1033-1041.
87. Gluckman E., Rocha V. Donor selection for unrelated cord blood transplants (Review). Curr Opin Immunol 2006, 18:565-570.
88. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
89. Kurtzberg J., Prasad V.K., Carter S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008, 112:4318-4327.
90. Eapen M., Klein J.P., Sanz G.F., et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011, 12:1214-1221.
91. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
92. Ohnuma K., Isoyama K., Ikuta K., et al. The influence of HLA genotyping compatibility on clinical outcome after cord blood transplantation from unrelated donors. J Hematother Stem Cell Res 2000, 9:541-550.
93. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia.[Erratum appears in Leukemia. 2009 Mar;23(3):630]. Leukemia 2009, 23:492-500.
94. Brunstein C.G., Wagner J.E., Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009, 113:5628-5634.
95. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001, 344:1815-1822.
96. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
97. Arcese W., Rocha V., Labopin M., et al. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica 2006, 91:223-230.
98. Wagner J.E., Barker J.N., Defor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
99. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997, 337:373-381.
100. Barker J.N., Scaradavou A., Stevens C.E. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010, 115:1843-1849.
101. Rocha V., Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients (Review). Bone Marrow Transplant 2008, 41:207-214.
102. Delaney C., Gutman J.A., Appelbaum F.R. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications (Review). Br J Haematol 2009, 147:207-216.
103. Robinson S.N., Simmons P.J., Yang H., et al. Mesenchymal stem cells in ex vivo cord blood expansion (Review). Baillieres Best Pract Res Clin Haematol 2011, 24:83-92.
104. de Lima M., McMannis J., Gee A., et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008, 41:771-778.
105. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
106. Claas F.H., Gijbels Y., van der Velden-de Munck J., van Rood J.J. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science 1988, 241:1815-1817.
107. Burlingham W.J., Grailer A.P., Heisey D.M., et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med 1998, 339:1657-1664.
108. van Rood J.J., Loberiza F.R., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002, 99:1572-1577.
109. Obama K., Utsunomiya A., Takatsuka Y., Takemoto Y. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant 2004, 34:897-899.
110. Shimazaki C., Fuchida S., Ochiai N., et al. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism. Br J Haematol 2004, 127:474-475.
111. van Rood J.J., Stevens C.E., Smits J., et al. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. PNAS 2009, 106:19952-19957.
112. van Rood J.J., Scaradavou A., Stevens C.E. Indirect evidence that maternal michrochimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. PNAS 2012, 109:2509-2514.
113. Rocha V., Spellman S., Zhang M.J., et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2012, 18:1890-1896.
114. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
115. Mathe G., Amiel J.L., Schwarzenberg L., et al. Successful allogeneic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemia effects. Blood 1965, 25:179-196.
116. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84:3948-3955.
117. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
118. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
119. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004, 103:1521-1526.
120. Passweg J.R., Stern M., Koehl U., Uharek L., Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation (Review). Bone Marrow Transplant 2005, 35:637-643.
121. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100:3825-3827.
122. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
123. Bornhauser M., Schwerdtfeger R., Martin H., et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004, 103:2860-2861.
124. Schaffer M., Malmberg K.J., Ringden O., Ljunggren H.G., Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004, 78:1081-1085.
125. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
126. Beelen D.W., Ottinger H.D., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005, 105:2594-2600.
127. Sun J.Y., Gaidulis L., Dagis A., et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 2005, 36:525-530.
128. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
129. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006, 12:876-884.
130. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12:828-836.
131. Sun J.Y., Dagis A., Gaidulis L., et al. Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients. Biol Blood Marrow Transplant 2007, 13:197-205.
132. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
133. Miller J.S., Cooley S., Parham P., et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
134. Valiante N.M., Uhrberg M., Shilling H.G., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997, 7:739-751.
135. Witt C.S., Dewing C., Sayer D.C., et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 1999, 68:1784-1789.
136. Toneva M., Lepage V., Lafay G., et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens 2001, 57:358-362.
137. Norman P.J., Carrington C.V., Byng M., et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immun 2002, 3:86-95.
138. Hsu K.C., Chida S., Geraghty D.E., Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism (Review). Immunol Rev 2002, 190:40-52.
139. Marsh S.G., Parham P., Dupont B., et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Immunogenetics 2003, 55:220-226.
140. Denis L., Sivula J., Gourraud P.A., et al. Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens 2005, 66:267-276.
141. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
142. Stringaris K., Adams S., Uribe M., et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1257-1264.
143. McQueen K.L., Dorighi K.M., Guethlein L.A., et al. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007, 68:309-323.
144. Chen C., Busson M., Rocha V., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006, 38:437-444.
145. Venstrom J.M., Gooley T.A., Spellman S., et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010, 115:3162-3165.
146. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
147. Symons H.J., Leffell M.S., Rossiter N.D., et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010, 16:533-542.
148. Kroger N., Binder T., Zabelina T., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82:1024-1030.
149. Parmar S., Del Lima M., Zou Y., et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 2009, 114:2884-2887.
150. Anderson E., Grzywacz B., Wang H., et al. Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. Blood 2009, 114:4753-4754.
151. Trowsdale J. HLA genomics in the third millennium (Review). Curr Opin Immunol 2005, 17:498-504.
152. Yunis E.J., Larsen C.E., Fernandez-Viña M., et al. Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens 2003, 62:1-20.
153. High-Resolution HLA Alleles and Haplotypes in the US Population. Bioinformatics - National Marrow Donor Program® (NMDP) Available at:, [Accessed [date]. 2012]. http://bioinformatics.nmdp.org/HLA/Haplotype_Frequencies/High_Res_HLA_Alleles_US_Pop/High-Resolution_HLA_Alleles_and_Haplotypes_in_the_US_Population.aspx.
154. Dawkins R., Leelayuwat C., Gaudieri S., et al. Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease (Review). Immunol Rev 1999, 167:275-304.
155. Jeffreys A.J., Kauppi L., Neumann R. Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet 2001, 29:217-222.
156. Allcock R.J., Atrazhev A.M., Beck S., et al. The MHC haplotype project: a resource for HLA-linked association studies (Review). Tissue Antigens 2002, 59:520-521.
157. Ahmad T., Neville M., Marshall S.E., et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003, 12:647-656.
158. Walsh E.C., Mather K.A., Schaffner S.F., et al. An integrated haplotype map of the human major histocompatibility complex. Am J Hum Genet 2003, 73:580-590.
159. Miretti M.M., Walsh E.C., Ke X., et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:634-646.
160. Smith W.P., Vu Q., Li S.S., et al. Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics 2006, 87:561-571.
161. Traherne J.A. Human MHC, architecture and evolution: implications for disease association studies (Review). Int J Immunogenet 2008, 35:179-192.
162. Baschal E.E., Aly T.A., Jasinski J.M., et al. Defining multiple common "completely" conserved major histocompatibility complex SNP haplotypes. Clin Immunol 2009, 132:203-214.
163. Morishima S., Ogawa S., Matsubara A., et al. Impact of highly conserved HLA haplotype on acute graft-versus-host disease. Blood 2010, 115:4664-4670.
164. Awdeh Z.L., Raum D., Yunis E.J., Alper C.A. Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. Proc Natl Acad Sci U S A 1983, 80:259-263.
165. Degli-Esposti M.A., Leaver A.L., Christiansen F.T., et al. Ancestral haplotypes: conserved population MHC haplotypes. Hum Immunol 1992, 34:242-252.
166. D'Alfonso S., Borelli I., Dall'Omo A., et al. The natural history of an HLA haplotype and its recombinants. Immunogenetics 1998, 48:8-15.
167. Baena A., Mootnick A.R., Falvo J.V., et al. Primate TNF promoters reveal markers of phylogeny and evolution of innate immunity. PLoS One 2007, 2:e621. [Electronic Resource].
168. Tay G.K., Witt C.S., Christiansen F.T., et al. Matching for MHC haplotypes results in improved survival following unrelated bone marrow transplantation. Bone Marrow Transplant 1995, 15:381-385.
169. Ketheesan N., Gaudieri S., Witt C.S., et al. Reconstruction of the block matching profiles. Hum Immunol 1999, 60:171-176.
170. Guo Z., Hood L., Malkki M., Petersdorf E.W. Long-range multilocus haplotype phasing of the MHC [erratum appears in Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9374]. PNAS 2006, 103:6964-6969.
171. Petersdorf E.W., Malkki M., Gooley T.A., Martin P.J., Guo Z. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007, 4:e8.
172. Donis-Keller H., Green P., Helms C., et al. A genetic linkage map of the human genome. Cell 1987, 51:319-337.
173. Stallings R.L., Ford A.F., Nelson D., et al. Evolution and distribution of (GT)n repetitive sequences in mammalian genomes. Genomics 1991, 10:807-815.
174. Schlotterer C., Tautz D. Slippage synthesis of simple sequence DNA. Nucleic Acids Res 1992, 20:211-215.
175. Davies J.L., Kawaguchi Y., Bennett S.T., et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994, 371:130-136.
176. Martin M., Mann D., Carrington M. Recombination rates across the HLA complex: use of microsatellites as a rapid screen for recombinant chromosomes [erratum appears in Hum Mol Genet 1995 Dec;4(12):2423]. Hum Mol Genet 1995, 4:423-428.
177. Martin M.P., Harding A., Chadwick R., et al. Characterization of 12 microsatellite loci of the human MHC in a panel of reference cell lines [erratum appears in Immunogenetics 1998 May;47(6):503]. Immunogenetics 1998, 47:131-138.
178. Carrington M., Marti D., Wade J., et al. Microsatellite markers in complex disease: mapping disease-associated regions within the human major histocompatibility complex. Microsatellites: Evolution and Applications 1999, 225-237. Oxford University Press, New York. D.B. Goldstein, C. Schlötterer (Eds.).
179. Foissac A., Fort M.L., Giraldo P., et al. Microsatellites in the HLA region: potential applications in bone marrow transplantation. Transplant Proc 1997, 29:2374-2375.
180. Carrington M., Wade J. Selection of transplant donors based on MHC microsatellite data. Hum Immunol 1996, 50:151-154.
181. Malkki M., Gooley T.A., Horowitz M.M., et al. Mapping MHC-resident transplantation determinants. Biol Blood Marrow Transplant 2007, 13:986-995.
182. Li S., Kawata H., Katsuyama Y., et al. Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci. Tissue Antigens 2004, 63:362-368.
183. Bettens F., Passweg J., Schanz U., et al. Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms. Biol Blood Marrow Transplant 2012, 18:608-616.
184. Wang D.G., Fan J.B., Siao C.J., et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998, 280:1077-1082.
185. Reich D.E., Cargill M., Bolk S., et al. Linkage disequilibrium in the human genome. Nature 2001, 411:199-204.
186. Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 1999, 22:139-144.
187. Kruglyak L. The use of a genetic map of biallelic markers in linkage studies. Nat Genet 1997, 17:21-24.
188. Cullup H., Dickinson A.M., Jackson G.H., et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001, 113:807-813.
189. Socie G., Loiseau P., Tamouza R., et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001, 72:699-706.
190. Cavet J., Dickinson A.M., Norden J., et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98:1594-1600.
191. Rocha V., Franco R.F., Porcher R., et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002, 100:3908-3918.
192. MacMillan M.L., Radloff G.A., Defor T.E., Weisdorf D.J., Davies S.M. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 2003, 121:597-604.
193. Cullup H., Dickinson A.M., Cavet J., Jackson G.H., Middleton P.G. Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003, 122:778-787.
194. Reddy P., Ferrara J.L. Immunobiology of acute graft-versus-host disease (Review). Blood Rev 2003, 17:187-194.
195. Dickinson A.M., Middleton P.G. Beyond the HLA typing age: genetic polymorphisms predicting transplant outcome (Review). Blood Rev 2005, 19:333-340.
196. Mullighan C.G., Bardy P.G. New directions in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:127-144.
197. Holler E., Rogler G., Brenmoehl J., et al. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet 2008, 35:381-384.
198. Tseng L.-H., Storer B., Petersdorf E., et al. IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 2009, 87:704-710.
199. Ferrara J.L. The cytokine modulation of acute graft-versus-host disease (Review). Bone Marrow Transplant 1998, 21(Suppl. 3):S13-S15.
200. Morgan G.J., Adamson P.J., Mensah F.K., et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 2005, 129:358-365.
201. Nedospasov S.A., Udalova I.A., Kuprash D.V., Turetskaya R.L. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. J Immunol 1991, 147:1053-1059.
202. Udalova I.A., Nedospasov S.A., Webb G.C., Chaplin D.D., Turetskaya R.L. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993, 16:180-186.
203. Schots R., Kaufman L., Van R.I., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003, 17:1150-1156.
204. Middleton P.G., Taylor P.R.A., Jackson G., Proctor S.J., Dickinson A.M. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998, 92:3943-3948.
205. Takahashi H., Furukawa T., Hashimoto S., et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 2000, 26:1317-1323.
206. Tambur A.R., Yaniv I., Stein J., et al. Cytokine gene polymorphism in patients with graft-versus-host disease. Transplant Proc 2001, 33:502-503.
207. Kogler G., Middleton P.G., Wilke M., et al. Recipient cytokine genotypes for TNF-alpha and IL-10 and the minor histocompatibility antigens HY and CD31 codon 125 are not associated with occurrence or severity of acute GVHD in unrelated cord blood transplantation: a retrospective analysis. Transplantation 2002, 74:1167-1175.
208. Bogunia-Kubik K., Polak M., Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 2003, 32:617-622.
209. Keen L.J., Defor T.E., Bidwell J.L., et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 2004, 103:3599-3602.
210. Bertinetto F.E., Dall'Omo A.M., Mazzola G.A., et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int J Immunogenet 2006, 33:375-384.
211. Shah R., Selby S.T., Yokley B., et al. TNF, LTA and TGFB1 genotype distributions among acute graft-vs-host disease subsets after HLA-matched unrelated hematopoietic stem cell transplantation: a pilot study. Tissue Antigens 2009, 74:50-56.
212. Harkensee C., Oka A., Onizuka M., et al. Single nucleotide polymorphisms and outcome risk in unrelated mismatched hematopoietic stem cell transplantation: an exploration study. Blood 2012, 119:6365-6372.
213. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming (Review). Immunogenetics 1994, 39:93-98.
214. Asea A., Kraeft S.K., Kurt-Jones E.A., et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000, 6:435-442.
215. Goral J., Shenoy S., Mohanakumar T., Clancy J. Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol 2002, 127:553-559.
216. Jarvis M., Marzolini M., Wang X.N., et al. Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease. Transplantation 2003, 76:849-853.
217. Bogunia-Kubik K., Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation 2005, 79:815-820.
218. Petersdorf E.W., Malkki M., Gooley T.A., et al. MHC-resistant variation affects risks after unrelated donor hematopoietic cell transplantation. Sci Transl Med 2012, 4:144ra101.